Ph2 double blind study of V940 in combo with pembro with NSCLC
Phase II Clinical Trial
V940-013- A Phase 2 randomized double-blind placebo-controlled study of V940 in combination with pembrolizumab and chemotherapy as first-line treatment for participants with metastatic squamous NSCLC (INTerpath-013)